We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+8.58%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.59B
AUM Growth
+$160M
Cap. Flow
-$54.6M
Cap. Flow %
-3.43%
Top 10 Hldgs %
16.55%
Holding
226
New
31
Increased
63
Reduced
63
Closed
27

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19M
2
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$16.3M
3
AMRS
Amyris Inc.
AMRS
+$14.3M
4
ESTA icon
Establishment Labs
ESTA
+$12.8M
5
SQSP
Squarespace, Inc.
SQSP
+$9.51M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$20M
2
NVCR icon
NovoCure
NVCR
+$14.8M
3
SEER icon
Seer Inc
SEER
+$14.5M
4
JBLU icon
JetBlue
JBLU
+$14.2M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 44.51%
2 Technology 13.21%
3 Financials 6.93%
4 Consumer Discretionary 6.6%
5 Industrials 5.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$35.3M 2.21%
363,708
-11,946
-3% -$970K
BBIO icon
2
BridgeBio Pharma
BBIO
$15.7B
$27.6M 1.73%
451,982
-37,641
-8% -$2.15M
RGEN icon
3
Repligen
RGEN
$8.3B
$27.3M 1.71%
136,652
-5,451
-4% -$1.06M
TGTX icon
4
TG Therapeutics
TGTX
$7.07B
$25.6M 1.61%
660,964
+35,177
+6% +$1.38M
KRNT icon
5
Kornit Digital
KRNT
$734M
$25.6M 1.6%
205,667
-146
-0.1% -$15.4K
ZLAB icon
6
Zai Lab
ZLAB
$2.05B
$25.1M 1.58%
141,881
+3,659
+3% +$589K
AVTR icon
7
Avantor
AVTR
$9.25B
$24.9M 1.56%
701,183
+20,283
+3% +$656K
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$24.4M 1.53%
598,261
+43,716
+8% +$1.62M
TWST icon
9
Twist Bioscience
TWST
$6.29B
$24.4M 1.53%
182,967
+20,232
+12% +$2.35M
ARGX icon
10
argenx
ARGX
$52B
$23.6M 1.48%
78,527
-7,601
-9% -$2.16M
OSH
11
DELISTED
Oak Street Health, Inc.
OSH
$22.5M 1.41%
383,390
+10,549
+3% +$628K
MPWR icon
12
Monolithic Power Systems
MPWR
$66B
$22.3M 1.4%
59,819
+5,230
+10% +$1.84M
VEEV icon
13
Veeva Systems
VEEV
$33.5B
$21.6M 1.36%
69,610
-854
-1% -$238K
EXAS
14
DELISTED
Exact Sciences
EXAS
$21.5M 1.35%
173,168
+4,884
+3% +$583K
NEO icon
15
NeoGenomics
NEO
$2.04B
$21.4M 1.34%
473,264
+2,812
+0.6% +$125K
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$21.3M 1.34%
227,839
-42,792
-16% -$3.94M
KRYS icon
17
Krystal Biotech
KRYS
$9.21B
$21.3M 1.34%
313,454
+8,765
+3% +$612K
INSP icon
18
Inspire Medical Systems
INSP
$1.5B
$21.2M 1.33%
109,746
+8,700
+9% +$1.73M
TXG icon
19
10x Genomics
TXG
$5.97B
$21.1M 1.32%
107,801
+21,406
+25% +$3.87M
CELL
20
DELISTED
PhenomeX Inc. Common Stock
CELL
$20.5M 1.29%
458,376
+125,042
+38% +$5.8M
ESTA icon
21
Establishment Labs
ESTA
$2.73B
$20.5M 1.29%
234,570
+172,330
+277% +$12.8M
AMRS
22
DELISTED
Amyris Inc.
AMRS
$20.4M 1.28%
1,248,778
+959,915
+332% +$14.3M
SDGR icon
23
Schrodinger
SDGR
$1.14B
$20.4M 1.28%
269,194
+7,532
+3% +$546K
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
$20.3M 1.28%
298,247
-29,695
-9% -$1.94M
GS icon
25
Goldman Sachs
GS
$303B
$20.1M 1.26%
52,961
-5,000
-9% -$1.79M
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Nicholas Investment Partners held 226 positions worth $1.59B, up 11% from $1.43B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Nicholas Investment Partners withdrew a net $54.6M in Q2 2021, closing 27 positions and reducing 63 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $20M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier, followed by Technology and Financials.

Against the trend, Nicholas Investment Partners opened a new position in Mirati Therapeutics, Inc. Common Stock worth $19.2M.

  • Nicholas Investment Partners's largest Q2 2021 buy was Mirati Therapeutics, Inc. Common Stock: 118,591 shares worth $19.2M.
  • Nicholas Investment Partners added most to Amyris Inc. in Q2 2021, an estimated $14.3M increase.
  • Nicholas Investment Partners's biggest Q2 2021 reduction was NovoCure, cutting an estimated $14.8M.
  • Nicholas Investment Partners fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, selling an estimated $20M.
  • Nicholas Investment Partners's ten largest holdings make up 17% of its $1.59B portfolio in Q2 2021.
  • Nicholas Investment Partners opened 31 new positions and closed 27 in Q2 2021.
  • Nicholas Investment Partners's portfolio value rose 11% quarter-over-quarter to $1.59B.

Based on Nicholas Investment Partners's 13F filing for Q2 2021, filed 10 Aug 2021.